Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant

Digestive and Liver Disease

Volumn 36, Issue 10, 2004, Pages 677-681

  Torre, F ^a   Mattioli, F ^a   Campo, N ^a   Delfino, A ^a   Basso, M ^a   Pelli, N ^a   Martelli, A ^a   Picciotto, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

HBV; Lamivudine; Resistant mutant

Indexed keywords

ASPARTIC ACID; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; TYROSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TYPING; WILD TYPE; ANTIBIOTIC RESISTANCE; BLOOD; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; RECURRENT DISEASE;

ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECURRENCE;

EID: 16644393612     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.03.020     Document Type: Article

References (16)

1. Lucey MR. Hepatitis B infection and liver transplantation: the art of the possible. Hepatology 1994;19:245-7.
2. Devlin J, Smith HM, O'Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994;21:204-10.
3. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995;35:1174-80.
4. Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000;61:367-73.
5. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36:41-66.
6. Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000;300:403-18.
7. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
8. Alien MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
9. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;10:4771-9.
10. Torre F, Campo N, Sinelli N, Brizzolara R, Andorno E, Valente U, et al. Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. Transplantation 2000;70:1111-2.
11. Shah VP, Midha K K, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991;16:249-55.
12. Hoetelmans RM, Profijt M, Mennhorst PL, Mulder JW, Beijnen JH. Quantitative determination of (-)-2′-deoxy-3′-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998;713:387-94.
13. Moyer TP, Temesgen Z, Enger R, Estes L, Charlson J, Oliver L, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999;45:1645-76.
14. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay R Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979;281:646-50.
15. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-88.
16. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001;120:1000-8.